Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pepgen Inc (PEPG)

Pepgen Inc (PEPG)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 389,114
  • Shares Outstanding, K 68,748
  • Annual Sales, $ 0 K
  • Annual Income, $ -89,980 K
  • EBIT $ -98 M
  • EBITDA $ -97 M
  • 60-Month Beta 1.91
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.15

Options Overview Details

View History
  • Implied Volatility 467.75% (+286.82%)
  • Historical Volatility 98.32%
  • IV Percentile 86%
  • IV Rank 42.70%
  • IV High 1,050.97% on 01/15/25
  • IV Low 33.17% on 09/05/25
  • Expected Move (DTE 4) 0.70 (12.31%)
  • Put/Call Vol Ratio 1.58
  • Today's Volume 566
  • Volume Avg (30-Day) 1,296
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 18,372
  • Open Int (30-Day) 16,913
  • Expected Range 4.96 to 6.36

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.38
  • Number of Estimates 5
  • High Estimate -0.27
  • Low Estimate -0.50
  • Prior Year -0.68
  • Growth Rate Est. (year over year) +44.12%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.70 +20.30%
on 11/14/25
6.72 -15.77%
on 11/28/25
+0.53 (+10.33%)
since 11/12/25
3-Month
1.47 +286.35%
on 09/15/25
6.72 -15.77%
on 11/28/25
+4.18 (+282.43%)
since 09/12/25
52-Week
0.88 +543.11%
on 04/09/25
6.72 -15.77%
on 11/28/25
+0.50 (+9.69%)
since 12/12/24

Most Recent Stories

More News
PepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Business and Legal Officer

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological...

PEPG : 5.66 (-1.39%)
PepGen Appoints Joseph Vittiglio, Esq., as Chief Business and Legal Officer

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological...

PEPG : 5.66 (-1.39%)
PepGen Announces Issuance of U.S. Patent for Proprietary PGN-EDODM1 Molecule

Composition of matter patent covers the Company’s novel PGN-EDODM1 molecule and serves as a cornerstone of its expanding patent portfolio

PEPG : 5.66 (-1.39%)
PepGen Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

– FREEDOM-DM1 15 mg/kg cohort demonstrated the highest mean splicing correction reported to date in DM1 patients – – FREEDOM2-DM1 5 mg/kg cohort on track to readout...

PEPG : 5.66 (-1.39%)
PepGen to Participate in Upcoming Investor Conferences

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological...

PEPG : 5.66 (-1.39%)
Analysts’ Opinions Are Mixed on These Healthcare Stocks: PepGen Inc. (PEPG) and Inventiva (IVA)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on PepGen Inc. (PEPG – Research Report) and Inventiva (IVA – Research Report).Elevate Your Investing Strategy: Take advantage...

IVA : 4.46 (-0.67%)
PEPG : 5.66 (-1.39%)
PepGen Highlights Progress in Therapy for DM1

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An update...

PEPG : 5.66 (-1.39%)
PepGen Announces Oral Presentations at the 30th Annual International Congress of the World Muscle Society

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological...

PEPG : 5.66 (-1.39%)
PepGen Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company developing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological...

PEPG : 5.66 (-1.39%)
PepGen Announces Pricing of $100 Million Public Offering

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company developing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological...

PEPG : 5.66 (-1.39%)

Business Summary

PepGen Inc. is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. PepGen Inc. is based in BOSTON.

See More

Key Turning Points

3rd Resistance Point 6.18
2nd Resistance Point 6.05
1st Resistance Point 5.86
Last Price 5.66
1st Support Level 5.54
2nd Support Level 5.41
3rd Support Level 5.22

See More

52-Week High 6.72
Last Price 5.66
Fibonacci 61.8% 4.49
Fibonacci 50% 3.80
Fibonacci 38.2% 3.11
52-Week Low 0.88

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar